残余胰腺复发高危病变的基因评估:异时多灶病变还是局部复发?
本研究对12例因残余胰腺第二高危病变行胰腺切除术的患者进行KRAS、TP53、CDKN2A、SMAD4突变及免疫组化分析和靶向二代测序。4例第二病变基因突变与原发一致(考虑局部复发),8例不一致(考虑异时多灶病变)。局部复发组累计复发率更高,异时多灶组累计疾病特异性生存率更高。基因评估可能有助于鉴别两者。
要点
- 残余胰腺第二高危病变的基因突变谱与原发一致提示局部复发,不一致提示异时多灶病变。
- 局部复发组术后累计复发率高于异时多灶组,异时多灶组累计疾病特异性生存率更高。
- 靶向二代测序显示异时多灶组第二病变创始突变与原发不同,局部复发组创始突变与原发相同。
核心结论
- 基因评估可能有助于鉴别残余胰腺异时多灶高危病变与局部复发。
研究设计与样本
- 对12例因残余胰腺第二高危病变行胰腺切除术的患者进行临床病理数据收集及基因分析。
- 对KRAS、TP53、CDKN2A、SMAD4四个基因进行突变和免疫组化分析,并行靶向二代测序。
主要发现
- 4例患者第二高危病变的四个基因突变与原发一致,考虑为局部复发。
- 8例患者第二高危病变的四个基因突变与原发不一致,考虑为异时多灶高危病变。
- 局部复发组第二高危病变切除后估计累计复发率高于异时多灶组。
- 异时多灶组估计累计疾病特异性生存率高于局部复发组。
- 靶向二代测序显示异时多灶组第二病变创始突变与原发不同,局部复发组创始突变与原发相同。
关键数值与推荐
- KRAS、TP53、CDKN2A、SMAD4四个基因突变与原发一致定义为局部复发,不一致定义为异时多灶高危病变。
临床怎么用
- 对残余胰腺第二高危病变患者,可考虑基因评估以鉴别异时多灶病变与局部复发,辅助预后判断。
局限性
- 样本量仅12例,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is difficult to determine whether a second high-risk lesion, including pancreatic ductal adenocarcinoma or high-grade pancreatic intraepithelial neoplasm, is a metachronous multifocal lesion or represents local recurrence after resection of the first high-risk lesion. This study attempts to clarify the characteristics of second high-risk lesions in the remnant pancreas using genetic analyses. METHODS: Clinicopathologic data were collected from 12 patients who underwent pancreatectomy for a second high-risk lesion in the remnant pancreas. We performed mutational and immunohistochemical analyses of 4 major genes-KRAS, TP53, CDKN2A, and SMAD4-associated with pancreatic ductal adenocarcinoma progression, as well as targeted next-generation sequencing. RESULTS: Mutations in the four genes in the second high-risk lesion were consistent with the first lesion in four patients but were inconsistent in the remaining eight patients, and thus we considered that the latter eight patients likely had metachronous multifocal high-risk lesions and the other four patients had local recurrence. The estimated cumulative recurrence rate after resection of the second high-risk lesion was greater in the local recurrence group compared with the metachronous multifocal group, and the estimated cumulative disease-specific survival rate was greater in the metachronous multifocal group. Targeted next-generation sequencing demonstrated that the second lesions in the metachronous multifocal high-risk lesion group showed differences in founder mutations compared with the first lesion. In the local recurrence group, the founder mutations in the second lesion were common with those in the first lesion. CONCLUSION: Genetic assessment might help discriminate metachronous multifocal high-risk lesions from local recurrence.
引用
- Gotoh Y, Ohtsuka T, Nakamura S, et al. Genetic assessment of recurrent pancreatic high-risk lesions in the remnant pancreas: Metachronous multifocal lesion or local recurrence? Surgery. 2018. PMID: 30497813. doi:10.1016/j.surg.2018.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。